ERBB2 and breast cancer: It has been demonstrated that lapatinib prevents mammary tumor development in mouse mammary tumor virus (MMTV)-erbB-2 transgenic mice; however, the chemopreventive effect in the study was based on long-term, high dose exposure to lapatinib (12 months, 75 mg/kg twice daily) [19].